Please login to the form below

Not currently logged in
Email:
Password:

US bill will force disclosure of doctor payments

A bill introduced in the US Senate will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors

A bill introduced in the US Senate on 6 September 2007 will force pharmaceutical companies and medical device manufacturers to report payments and gifts to doctors, according to the New York Times.

Companies with at least USD 100m in annual sales would have to disclose gifts or payments exceeding USD 25 in value each quarter, and the information would then be posted on a publicly accessible website.

Companies will have to disclose any payment or benefit made "directly, indirectly, through an agent, subsidiary or other third party", which might include payments by universities and by companies that organise conferences for Key Opinion Leaders (KOLs) with drug or medical device manufacturer funding.

Funding of continuing medical education programmes would also need to be disclosed. No-cost drug samples and financing for clinical trials would not have to be disclosed, according to the bill.

Senate Finance Committee member Chuck Grassley (Republican, Iowa), who is one of the bill's authors, said: "The public has no way to know whether a doctor's been given money that might affect prescribing habits."

Ken Johnson, senior vice-president of the Pharmaceutical Research and Manufacturers of America (PhRMA), countered: "A new law is not necessary when pharmaceutical marketing is already heavily regulated by the FDA."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics